Is Alpelisib a treatment drug for triple-negative breast cancer?

Alpelisib (Alpelisib)-Piqray is an oral targeted drug that mainly targets the PI3Kα signaling pathway and plays a role in patients with HR+ (hormone receptor positive) and HER2- advanced breast cancer who carry PIK3CA mutations. By selectively inhibiting the PI3Kα pathway, it blocks tumor cell proliferation signals and promotes cell apoptosis, thereby achieving the effect of delaying disease progression. Triple-negative breast cancer (TNBC) is characterized by negative estrogen receptor (ER), progesterone receptor (PR) and HER2. Such patients lack endocrine and HER2 targets, so Apelvis is not suitable for the treatment of TNBC. In TNBC, the clinical efficacy of apelvis is limited, and there is insufficient evidence to support its use as a standard treatment option.

Triple-negative breast cancer patients usually rely on chemotherapy, immunotherapy or other targeted drugs, such as anti-PD-1/PD-L1 antibodies and PARP inhibitors. Although the PI3K pathway may be active in some TNBC patients, there is a lack of clear clinical evidence that apelvis can significantly improve the prognosis of TNBC patients. The use of apelvis must be based on PIK3CA mutation test results and is only suitable for hormone receptor-positive, HER2-negative patients.

In general, Apelvis is an important targeted drug for patients with HR+/HER2- advanced breast cancer. It provides effective treatment options for patients with PIK3CA mutations by precisely inhibiting the PI3Kα signaling pathway, but it does not fall into the category of triple-negative breast cancer treatment drugs. Patients should complete genetic testing before use to ensure targeted medication, and combine it with endocrine therapy to obtain maximum efficacy. During the medication process, blood sugar, liver function and other safety indicators need to be closely monitored, and the dosage or treatment plan should be adjusted in a timely manner. Through scientific medication and regular follow-up, patients can achieve a longer progression-free survival while maximizing their quality of life and achieving the best balance between disease control and safety.

Reference materials:https://www.piqray.com/